Related Experiment Video
Updated: Feb 7, 2026

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
Small Activating RNAs: Towards Development of New Therapeutic Agents and Clinical Treatments
Sen-Mao Li1,2, Jia Hu1
1Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Background:
Small double-strand RNAs (dsRNAs) molecules are able to activate endogenous genes via an RNA-based promoter-targeting mechanism. Like RNA interference (RNAi), RNA activation (RNAa) is an evolutionarily conserved mechanism that is present in diverse eukaryotic organisms ranging from yeast to humans.
Methods:
The small activating RNAs (saRNAs) that are involved in RNAa have been successively used to activate gene expression in cultured cells. Thus, this emergent technique might allow us to develop biotechnological and therapeutic applications without the need to synthesize hazardous construct systems that harbor exogenous DNA sequences.
Result And Conclusion:
Accordingly, this article aims to provide insights into how RNAa cellular machinery can be manipulated to activate gene expression and for more effective clinical treatments of diverse diseases.
Related Concept Videos
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
lncRNA - Long Non-coding RNAs
lncRNA - Long Non-coding RNAs
piRNA - Piwi-interacting RNAs
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

